VBIV, a prominent player in the biotechnology sector, has recently hit a 52-week low, trading at a mere 0.4467 USD. This marks a significant downturn for the company, which has been grappling with a challenging market environment. The 52-week low data underscores the extent of the company's struggle, as it has been unable to maintain its previous price levels. Adding to the company's woes, Paulson Capital , a major investor, has seen a 1-year change of -56.59%. This substantial decrease further illustrates the difficulties VBIV has faced over the past year. Despite these challenges, the company remains committed to its strategic objectives and is focused on turning the tide in the coming months.
In other recent news, VBI Vaccines (NASDAQ:VBIV) Inc. has announced promising interim data from a Phase 2b study of their experimental cancer vaccine, VBI-1901. The vaccine, currently being tested on patients with recurrent glioblastoma (rGBM), has shown a 43% disease control rate in the study arm. Seven patients treated with VBI-1901 demonstrated one partial tumor response and two stable disease observations, marked by a significant 67% reduction in tumor size after two doses. In contrast, the control arm, receiving standard-of-care therapy, observed a 0% disease control rate, with most patients experiencing significant tumor growth.
The FDA has granted VBI-1901 Fast Track and Orphan Drug Designations, potentially expediting the drug's development process. Further interim data, including additional tumor response and initial survival data, is expected in the fourth quarter of 2024. VBI-1901, using VBI's enveloped virus-like particle technology, targets cytomegalovirus antigens prevalent in multiple solid tumors, including GBM, aiming to stimulate an immune response against these antigens. These are the recent developments in the ongoing research by VBI Vaccines Inc.
InvestingPro Insights
As VBIV navigates through its financial challenges, real-time data from InvestingPro sheds light on its current market position. With a market capitalization of just 16.75 million USD, the company is relatively small within the biotechnology sector. The revenue growth figures are striking, showing a 553.09% increase over the last twelve months as of Q1 2024, which may indicate a potential turnaround or a significant event that has positively impacted sales. However, this growth has not yet translated into profitability, as evidenced by a negative gross profit margin of -24.02% and an operating income margin of -505.3%. These metrics suggest that despite the increase in revenue, the company is not generating profits from its operations.
InvestingPro Tips highlight that VBIV operates with a significant debt burden and has been quickly burning through cash, which could be a concern for investors looking for sustainable growth. Additionally, the stock has experienced high volatility, with the price taking a significant hit over the last week, declining by 19.19%. Analysts predict the company will be profitable this year, a sentiment that could provide a glimmer of hope for investors. For those considering VBIV as an investment opportunity, it's worth noting that the company does not pay dividends, which may influence the decision for income-focused portfolios.
For readers seeking to delve deeper into the financial analysis of VBIV, InvestingPro offers a comprehensive set of additional tips. There are 11 more InvestingPro Tips available that can provide further insights into the company's performance and prospects. Take advantage of the insights available on InvestingPro by using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.